Introduction
============

Use of coronary artery bypass grafting (CABG) has been increasing rapidly over the last decade in China. Acute kidney injury (AKI) after CABG is common ([@b21]; Rosner & Okusa 2006). Epidemiologic evidences have suggested that not only the cardiac surgery-associated AKI (CSA-AKI) itself ([@b9]; [@b6]; [@b3]), but also the lack of recovery from CSA-AKI are related to longterm adverse prognoses ([@b16]; [@b20]; [@b17]). However, there are no efective treatments to improve renal recovery. One important barrier to progress in this area has been the lack of a reliable biomarker to predict recovery in individual patients. The ability to predict poor renal recovery would be extremely valuable for clinical decisions and to guide future research ([@b18]).

Prognostic biomarkers of AKI based on the physiology of renal recovery might also help to predict AKI recovery ([@b17]). However, few studies have stressed this issue, except a recent investigation using a panel of urine biomarkers ([@b18]). Cardiopulmonary bypass (CPB) during CABG is recognized as a cause of complex systemic infammatory and oxidative stress responses which signifcantly contribute to CSA-AKI and non-recovery of renal function ([@b5]; [@b2]; Liu & Brakeman 2008; [@b19]; [@b17]). Advanced oxidation protein products (AOPPs) are oxidized proteins and are used widely as biomarkers of infammation and oxidative stress ([@b22]; [@b4]). AOPPs can activate infammatory cells ([@b22]) and contribute to the progression of renal failure ([@b11]). Therefore, they are potential biomarkers for predicting renal recovery. In critically ill subjects, AOPP levels were shown to be higher in AKI patients compared with those in non-AKI patients, and AOPP levels were associated with AKI severity ([@b10]).

The aim of the present study was to assess the prognostic performance of serum levels of AOPPs for the recovery of CSA-AKI after CABG.

Material and methods
====================

This observational study complied with the tenets of the Helsinki Declaration. It was approved by the Research Ethics Committee of Guangdong General Hospital (Guangzhou, China). Written informed consent was obtained from each participant.

Study population
----------------

We retrospectively investigated all the subjects undergoing CABG between September 2007 and December 2008 from a prospective cohort in the Guangdong Cardiovascular Institute (which is one of the three major cardiovascular centers in China). In these patients, creatinine levels in serum were assessed every day for 7 days as a routine measurement for monitoring AKI. Exclusion criteria were: history of preoperative renal replacement therapy (RRT); estimated glomerular fltration rate (eGFR) \<15 mL/min/1.73 m^2^; previous cardiac surgery; emergency or salvage CABG; potential pulmonary, endocardial or urinary infections (according to local protocols; by clinical manifestations; blood and urine examination; X-ray and cardiac ultrasonography) before hospital admission or during hospital stay; death of the patient; or loss of the patient to follow-up \<3 months after surgery.

Defnitions
----------

Data obtained at the closest time point before surgery were defned as "baseline data". The stratifcation of cardiac risk was evaluated by the European System for Cardiac Operative Risk Evaluation (EuroSCORE) with slight modifcations to the defnition of neurological disease, recent myocardial infarction and emergency surgery. A close approximation of the modifed edition had been validated ([@b23]). Renal function was evaluated by the eGFR, which was calculated by the modifed diet and renal disease (MDRD) formula for Chinese populations ([@b13]). AKI was diagnosed and graded by the Acute Dialysis Quality Initiative (ADQI) consensus of RIFLE criteria based on serum creatinine levels ([@b1]): "Risk": increase in creatinine of 1.5--2.0-fold from baseline."Injury": increase in creatinine of 2--3-fold from baseline."Failure": increase in serum creatinine of \>3-fold from baseline."Lose": need for RRT for \>4 weeks."End-stage kidney disease (ESKD)": need for dialysis for \>3 months.

Recovered AKIs (rAKI) were included as completely recovered AKI (crAKI) and partially recovered AKI (prAKI) using RIFLE criteria at 3 months. crAKI was observed if patients returned to their baseline classifcation within the RIFLE criteria. prAKI was noted if there was a persistent change in RIFLE classifcation (R, I, or F). Non-recovered AKI (nrAKI) was observed if there was a persistent need for RRT ([@b1]). As a result, non-completely recovered AKI (ncrAKI) was composed of prAKI and nrAKI ([Figure 1](#fig1){ref-type="fig"}). nrAKI and ncrAKI were defned as adverse outcomes of AKI recovery.

![Renal outcomes according to diferent defnitions. rAKI, recovered AKI; crAKI, complete-recovered AKI; nrAKI, non-recovered AKI; ncrAKI, non-complete recovered AKI.](tbmk17-507-f1){#fig1}

Laboratory measurements
-----------------------

Serial serum samples were obtained from patients with AKI at baseline, 2 days, 7 days, and 3 months, and from controls at baseline, 2 days, and 7 days, after surgery. Fresh serum samples were used for the measurement of serum creatinine, whereas samples for the measurement of AOPPs were stored at --80°C until use. Serum AOPP levels were determined as described previously ([@b22]; [@b4]). Briefy, 200 µL of serum was diluted 1:5 in phosphate-bufered saline (PBS) and mixed with 20 µL of acetic acid. In the standard wells for creation of the standard curve, 10 µL of potassium iodide (Sigma-Aldrich, St Louis, MO, USA) was added to 200 µL of chloramine-T solution (Sigma-Aldrich) followed by 20 µL of acetic acid. The absorbance of the reaction mixture at 340 nm was analyzed in a microplate reader (Thermo Multiskan MK3, Vantaa, Finland) within 3 min of adding acetic acid. AOPP levels were expressed as µmol/L of chloramine-T equivalents.

Statistical analyses
--------------------

Continuous variables are mean values ± SD or medians (25th and 75th percentile) and categorical data are percentages. Multiple groups were compared using the χ^2^ test for nominal variables. ANOVA (with Bonferroni correction) or the Kruskal-Wallis test was employed for numerical variables if appropriate. The AOPP level at baseline and after surgery was compared using the paired *t*-test. Spearman\'s correlation coefcient (*r*~s~) was used to assess the correlation between two variables. Univariate and multivariate logistic regression analyses were done to assess the efect of AOPPs on the adverse outcomes of renal recovery. Odds ratios (ORs) and their associated 95% confdence intervals (95% CIs) were estimated. To compare the discriminatory value of AOPP levels for renal recovery, a receiver-operating characteristic (ROC) curve was plotted and the areas under the ROC curve (ROC AUC) calculated. Statistical procedures were undertaken using SPSS software (version 13.0; SPSS, Chicago, IL, USA). Two-tailed tests were carried out for all comparisons. *p* \< 0.05 was considered signifcant.

Results
=======

Patient characteristics and outcomes
------------------------------------

A total of 185 patients fulflled the inclusion criter ia (including 58 patients with AKI). From 127 subjects without AKI, 58 controls were selected randomly. Baseline characteristics of the controls and patients with AKI are shown in [Table 1](#tbl1){ref-type="table"}. Patients with AKI were older and had a higher urine albumin--creatinine ratio and higher EuroSCORE than controls. There were 22 in RIFLE R, 17 in RIFLE I, and 19 in RIFLE F in the 58 patients with AKI. Among them, 4 patients with RIFLE I and all the 17 patients with RIFLE F received RRT, and 13 patients had nrAKI and 27 patients had ncrAKI 3 months after surgery. These patients with AKI were further divided into two groups according to renal recovery ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}). Patients with nrAKI were more likely to be older and to have a longer CPB time compared with patients with rAKI. Patients with nrAKI were older and had a higher EuroSCORE compared with those with ncrAKI.

###### 

Demographic, clinical characteristics and blood chemistry data at baseline.

                                           Total (*n* = 116)   Controls (*n* = 58)   AKI (*n* = 58)      *p* value
  ---------------------------------------- ------------------- --------------------- ------------------- -----------
  Age (years)                              63 ± 7              61 ± 6                64 ± 7              .004
  Females (%)                              45.7                40.0                  55.2                .094
  Estimated GFR (mL/min/1.73 m^2^)         86.3 (67.8, 93.2)   88.2 (79.0, 93.4)     84.4 (50.3, 93.6)   .228
  Left ventricle ejection faction (%)      51.0 (37.3, 55.6)   51.2 (41.1, 55.9)     51.0 (33.1, 55.1)   .303
  Cardiopulmonary bypass time (minutes)    118 ± 23            122 ± 24              115 ± 23            .079
  Urine albumin--creatinine ratio (mg/g)   18.9 (11.1, 32.7)   14.7 (9.9, 25)        24.1 (12.2, 38.9)   .013
  Diabetes (%)                             24.1                17.2                  31.0                .083
  EuroSCORE score (point)                  5 (3, 8)            4 (3, 6)              6 (4, 8)            .002

###### 

Clinical features between diferent groups with recovered AKI and non-recovered AKI.

                                          nrAKI (*n* = 13)       rAKI (*n* = 45)        *p* value
  --------------------------------------- ---------------------- ---------------------- -----------
  Age (years)                             68 ± 7                 63 ± 7                 .039
  Female(%)                               51.1                   53.8                   .862
  Estimated GFR (mL/min/1.73 m^2^         78.3 (37.9, 92.3)      85.4 (56.6, 96.5)      .182
  Serum creatine on day 7(µmol/L)         328.7 (124.3, 785.4)   295.2 (139.6, 687.5)   .232
  Left ventricle ejection faction (%)     46.4 (28.9, 52.9)      51.2 (33.5, 55.6)      .292
  Cardiopulmonary bypass time (minutes)   134 ± 17               119 ±24                .035
  Albumin-creatinine ratio (mg/g)         17.5 (14.3, 30.7)      25.1 (11.5, 40.1)      .199
  Diabetes (%)                            46.2                   26.7                   .319
  EuroSCORE score (points)                8.2 ± 4.6              6.2±3.4                .093

###### 

Clinical features between groups with completely recovered AKI and non-completely recovered AKI.

                                          ncrAKI (*n* = 27)      crAKI (*n* = 31)       *p* value
  --------------------------------------- ---------------------- ---------------------- -----------
  Age (years)                             65 ± 6                 64 ± 8                 .366
  Female (%)                              48.4                   55.6                   .586
  estimated GFR (mL/min/1.73m^2^)         84.3 (44.7, 96.3)      84.4 (56.5, 92.1)      .919
  Serum creatine on day 7 (µmol/L)        308.7 (174.3, 815.3)   275.1 (149.5, 787.5)   .132
  Left ventricle ejection faction (%)     40.2 (28.9, 51.7)      53.4 (38.2, 55.9)      .011
  Cardiopulmonary bypass time (minutes)   120 ± 22               124 ± 25               .621
  Albumin-creatinine ratio (mg/g)         16.5 (10.4, 31.1)      25.1 (16.4, 41.1)      .114
  Diabetes (%)                            37.0                   25.8                   .356
  EuroSCORE score (points)                8 (7, 9)               4 (3, 6)               \<.001

Kinetics of AOPPs
-----------------

AOPP level at 7 days increased by ≃50 µmol/L in the nrAKI group and increased by 40 µmol/L in the ncrAKI group after surgery. Patients with nrAKI had a higher AOPP level 7 days after surgery than patients with rAKI and controls (121.2 ± 37.9 *vs* 88.3 ± 22.9 and 71.7 ± 28.0), as well as patients with ncrAKI than patients with crAKI and controls (115.5 ± 32.4 *vs* 78.4 ± 11.6 and 71.7 ± 28.0) ([Figure 2](#fig2){ref-type="fig"}). Given that the levels of AOPPs at baseline and 2 days after surgery were comparable among groups, the results of the following two-time points are not shown. The AOPP level of all the patients with AKI and of controls 7 days after surgery was correlated to EuroSCORE values and CPB time, and had a mild inverse correlation with the baseline values of left ventricular ejection faction ([Table 4](#tbl4){ref-type="table"}).

![Kinetics of AOPP level in diferent groups. AOPP levels at baseline, days 2 and days 7 after surgery in controls, patients with recovered AKI and patients with non-recovered AKI (a) or in controls, patients with completely recovered AKI and patients with non-completely recovered AKI (b). rAKI, recovered AKI; crAKI, complete-recovered AKI; nrAKI, non-recovered AKI; ncrAKI, non-completely recovered AKI. \**p* \< .05 AOPP level between patients with nrAKI and controls. \#*p* \< .05 AOPP level between patients with nrAKI and patients with rAKI. †*p* \< .05 AOPP level between the baseline and at 7 days in the patients with nrAKI. ‡*p* \< .05 AOPP level between patients with ncrAKI and controls. §*p* \< .05 AOPP level between patients with ncrAKI and patients with crAKI. ¶*p* \< .05 AOPP level between the baseline and at 7 days in the patients with ncrAKI.](tbmk17-507-f2){#fig2}

###### 

Relationship between AOPP level at 7 days and clinical indices.

                                    *r*~s~    *p* value
  --------------------------------- --------- -----------
  Age                               0.108     .247
  Left ventricle ejection faction   --0.227   .014
  eGFR                              --0.156   .096
  Cardiopulmonary bypass time       0.159     .088
  EuroSCORE                         0.510     \<.001

AOPP levels as prognostic risk factors for adverse outcomes of AKI recovery
---------------------------------------------------------------------------

To evaluate the independent efect of AOPP level at 7 days on nrAKI or ncrAKI, AOPP level and variables with *p* \< 0.10 in the univariate analysis ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}) were candidates for the multivariable logistic analysis. An increased level of AOPPs of 10 µmol/L was related to an increased prevalence of nrAKI and ncrAKI of 50.9% and 188.3%, respectively ([Table 5](#tbl5){ref-type="table"}).

###### 

AOPP as risk factors for adverse outcomes of AKI recovery.

                   For non-recovered AKI   For non-completely recovered AKI                                                         
  ---------------- ----------------------- ---------------------------------- ------- -------------- ------- -------------- ------- -------------
  AOPP at 7 days   1.421                   1.126--1.794                       1.509   1.102--2.067   3.217   1.658--6.242   2.883   1437--5.787

Adjusted by age, cardiopulmonary bypass time and EuroSCORE.

Adjusted by left ventricle ejection faction and EuroSCORE.

Prognostic performance of AOPP for adverse outcomes of AKI recovery
-------------------------------------------------------------------

In the patients with AKI, the AOPP level at day 7 was a good biomarker for predicting nrAKI (nrAKI *vs* rAKI) and ncrAKI (ncrAKI *vs* crAKI) using ROC curves analyses. The prognostic strength of AOPP levels for adverse outcomes of AKI recovery is shown in [Table 6](#tbl6){ref-type="table"}.

###### 

Predictive performances of serum AOPP at day 7 for adverse outcomes of AKI recovery.

                                          AUC     AUC 95% CI     Sensitivity   Specificity   Positive predictive value   Negative predictive value
  --------------------------------------- ------- -------------- ------------- ------------- --------------------------- ---------------------------
  AOPP for non-recovered AKI              0.791   0.644--0.937                                                           
   80                                                            92.3          44.4          32.4                        95.2
   90                                                            69.2          71.1          40.9                        88.9
   100                                                           53.9          84.4          50.0                        86.4
  AOPP for non-completely recovered AKI   0.903   0.822--0.984                                                           
   80                                                            92.6          61.3          67.6                        90.5
   90                                                            74.1          93.6          90.9                        80.6
   100                                                           48.2          96.8          92.9                        68.2

Discussion
==========

Patients with poor recovery from AKI had a higher AOPP level, and an increased AOPP level was associated with nrAKI and ncrAKI. These fndings demonstrating that the AOPP level was a potential candidate for predicting adverse recovery from AKI. ROC curve analyses confrmed that the AOPP level had good prognostic value for predicting adverse outcomes after AKI.

Pre-existing proteinuria is associated with CSA-AKI ([@b7]). However, the urine albumin-creatinine ratio was not associated with renal recovery in the present study. Given that tubular injury, renal hemodynamics and intestinal infammation have key roles in renal recovery, albuminuria (a classical biomarker of glomerular injury) might not be a marker for recovery from AKI. No authors have demonstrated that the level of albuminuria is a risk factor for renal recovery. At the very least, the present study suggested that albuminuria was not a strong prognostic factor for renal recovery.

The lifespan of oxidized albumin (the main component of AOPPs) is shorter than that of native albumin ([@b8]), but the kinetics of AOPP in CABG patients has not been investigated. We studied AOPP levels at 2 days and 7 days after CABG. The AOPP level at day 7 but not at day 2 had good prognostic value for renal recovery, but an optimized time point for measurement of the AOPP level needs to be investigated.

There were some limitations to our study. Results were from a relatively small number of patients in a single center. Tus, the results will need to be validated in a larger population. In addition, our study focused only on the AKI recovery after CABG. As a result, the serum level of AOPPs in controls undergoing CABG in the present study was higher than that of health controls in the same center ([@b4]; data not shown). We were not able to generalize our results to all cases of AKI. However, this homogenous study is possibly a better model for the prediction of adverse AKI recovery in such a population with a higher baseline level of AOPP. Finally, renal outcomes were followed up for only 3 months based on the suggestion of ADQI consensus. Late recovery of AKI after 3 months in patients requiring RRT is also recognized, but it is uncommon ([@b15]). Therefore, the value of AOPP levels for the long-term recovery from AKI remains to be validated.

In conclusion, increased AOPP levels 7 days after CABG were associated with adverse outcomes of AKI recovery (nrAKI and ncrAKI) in CABG patients in a Chinese population. AOPP levels had good prognostic value for predicting adverse renal recovery.
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